Minneapolis, Minnesota Clinical Trials

A listing of Minneapolis, Minnesota clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 4 clinical trials
None
CASCARA: Castration Sensitive Carboplatin Cabazitaxel and Abiraterone

This is a phase II clinical trial in patients with metastatic castration sensitive prostate cancer. The objective of the study is to determine the efficacy and further define the safety of the treatment combination. This study will evaluate dose levels of carboplatin AUC 4 with cabazitaxel 20 mg/m2. Patients will …

luteinizing hormone-releasing hormone agonist
metastasis
prednisone
abiraterone
carboplatin
Masonic Cancer Center at University of Minnesota
 (1.9 away) Contact site
  • 2 views
  • 03 Jun, 2021
  • +7 other locations
None
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

This randomized phase II trial studies how well abiraterone acetate and antiandrogen therapy, with or without cabazitaxel and prednisone, work in treating patients with castration-resistant prostate cancer previously treated with docetaxel that has spread to other parts of the body. Androgens can cause the growth of prostate cancer cells. Hormone …

hormone therapy
metastasis
prednisone
adenocarcinoma
tumor cells
Hennepin County Medical Center
 (0.8 away) Contact site
  • 1524 views
  • 11 May, 2021
  • +470 other locations
None
A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery

Patients with post-prostatectomy PSA (Prostate Specific Antigen) recurrences with aggressive disease features will receive salvage radiation therapy and standard androgen deprivation therapy (ADT) or enhanced ADT to determine if there is any improvement in progression-free survival when enhanced ADT is used compared to standard ADT.

luteinizing hormone-releasing hormone agonist
gonadotropin
adenocarcinoma
antiandrogens
enzalutamide
HealthPartners, Inc.
 (4.5 away) Contact site
  • 118 views
  • 25 Nov, 2021
  • +110 other locations
None
Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide

This is a prospective, randomized, open-label phase II study comparing cognitive outcomes between men with non-metastatic and metastatic castration-resistant prostate cancer (mCRPC or M0CRPC) treated with darolutamide or enzalutamide. Approximately 132 patients will be enrolled. Eligible patients will be randomized in a 1:1 fashion to treatment with enzalutamide 160 mg …

University of Minnesota
 (1.9 away) Contact site
  • 0 views
  • 08 Sep, 2021
  • +6 other locations